The expression of small, non-coding RNA or microRNAs (miR), is frequently deregulated in human cancer, but how these pathways affect disease progression is still largely elusive. Here, we report on a miR, miR-296, which is progressively lost during tumor progression and correlates with metastatic disease in colorectal, breast, lung, gastric, parathyroid, liver and bile ducts cancers. Functionally, miR-296 controls a global cell motility gene signature in epithelial cells by transcriptionally repressing the cell polarity-cell plasticity module, Scribble (Scrib). In turn, loss of miR-296 causes aberrantly increased and mislocalized Scrib in human tumors, resulting in exaggerated random cell migration and tumor cell invasiveness. Reexpression of miR-296 in MDA-MB231 cells inhibits tumor growth in vivo. Finally, miR-296 or Scrib levels predict tumor relapse in hepatocellular carcinoma patients. These data identify miR-296 as a global repressor of tumorigenicity and uncover a previously unexplored exploitation of Scrib in tumor progression in humans.
Introduction
A network of small, non-coding RNA or microRNAs (miR) has attracted attention as regulators of gene expression (Bartel, 2004) , influencing human diseases (Garzon et al., 2009) . In cancer, the systematic cataloging of deregulated miR expression in transformed cells compared with normal tissues (Lu et al., 2005) has helped uncovering novel transcriptional networks relevant to cell invasion (Valastyan et al., 2009 ) and metastasis as main drivers of unfavorable disease outcome in humans (Calin and Croce, 2006) .
In this context, perturbation of a normal apical-basal polarity in epithelial cells (Etienne-Manneville, 2008 ) is thought of as one of the earliest phenotypical changes in cellular transformation (Zhan et al., 2008; Ouyang et al., 2010) , heralding invasive cancer (Hanahan and Weinberg, 2000) . The transcriptional programs underlying this process are not completely understood, but so-called cell polarity-cell plasticity modules, for instance the mammalian homologs of Drosophila melanogaster Scribble (Scrib), atypical protein kinase C or Crumbs have a key role in apical-basal polarity of epithelia, cell orientation (Etienne-Manneville, 2008 ) and directional cell movements (Petrie et al., 2009) . In this context, loss of polarity proteins in Drosophila (Bilder et al., 2000) or mammalian cells (Etienne-Manneville, 2008) deregulates cell proliferation (Dow et al., 2008; Wu et al., 2010) , survival (Zhan et al., 2008) , epithelial-mesenchymal transition (Bahri et al., 2010) and random cell migration (Osmani et al., 2006) , suggesting that these molecules may function in an evolutionary-conserved pathway of tumor suppression in vivo Wu et al., 2010) .
In this study, we aimed at identifying novel miR regulators of tumor progression conserved in animal models and in epithelial human cancers, irrespective of the cancer origin. We found that miR-296, a miR previously associated with angiogenic endothelial cells (Wurdinger et al., 2008) or to prostate cancer (Wei et al., 2010) , functions as a global repressor of tumorigenicity and that, this pathway, different from previous models Wu et al., 2010) , involves deregulation and subcellular mislocalization of Scrib in metastatic human cancer (Etienne-Manneville, 2008) .
Results

Loss of miR-296 expression during tumorigenesis
We began this study by profiling the expression of 132 orthologous miRs in microdissected pancreatic islets isolated from rat insulin promoter-T antigen (RIP-TAg) transgenic mice (Hanahan, 1988) , an established model of tumor progression, suitable for miR analysis (Olson et al., 2009) . Islets from RIP-TAg mice exhibited extensive changes in miR expression during oncogenic transformation (4-6 weeks) and evolution to invasive pancreatic islet cell carcinoma (10 weeks; Supplementary Figure 1a ). In this analysis, miR-296 was consistently downregulated throughout all stages of islet tumorigenesis in vivo (Figure 1a) . Conversely, miR-296 was expressed at comparable levels in non-transgenic (NT) islets at the same time intervals ( Figure 1a ). As control, oncogenic miRs, including miR-21 (Seike et al., 2009; Supplementary Figure 1b) or miR-19a (Olson et al., 2009; Supplementary Figure 1c) , were upregulated in transgenic islets, but not in aged-matched controls. In addition, unrelated miRs, for instance miR-452 (Supplementary Figure 1d) or miR-216 (Supplementary Figure 1e) , were indistinguishably expressed in NT or RIP-TAg pancreatic tissues.
When analyzed in human samples, miR-296 levels were profoundly repressed in various cultured-tumor cell lines representative of breast, lung, colorectal or liver adenocarcinoma, compared with normal human mammary epithelial cells (HMEC; Supplementary   Figure 2a) . Similarly, miR-296 expression was progressively lost in 86% of patient samples representative of the colorectal adenoma-to-carcinoma transition (13 out of 16 patients, P ¼ 0.0007; Table 1 ), compared with matched-normal mucosa (Figure 1b) . A comparable pattern was observed in disparate, genetically heterogeneous tumor types (Table 1) , where miR-296 expression was frequently lost in primary (13 out of 20 patients, Po0.05), as well as metastatic lesions (15 out of 20 patients, P ¼ 0.009; Table 1 and Supplementary  Figure 2b) . When correlated to disease outcome, loss of miR-296 levels in patients with hepatocellular carcinoma (HCC; Augello et al., 2009 ), compared with matched-normal liver (Figure 1c ), was associated with considerably shortened disease-free survival (hazards ratio ¼ 2.4; Figure 1d ).
Regulation of tumor cell motility by miR-296
Manipulation of miR-296 levels by transfection of antagomir (a-miR-296; Supplementary Figure 3a) or, conversely, pre-miR-296 (p-miR-296; Supplementary Figure 3b ) had no effect on cell cycle transitions in various tumor types, by DNA content analysis and flow cytometry (Supplementary Figure 3c) . Conversely, Figure 1 Loss of miR-296 expression in human cancer. (a) Pancreatic islets from NT or RIP-Tag islets were analyzed for miR-296 expression at the indicated time intervals by quantitative PCR (RQ). Mean ± s.d. of replicates. (b) Analysis of miR-296 expression in 16 patients with metastatic colon adenocarcinoma. Bars correspond to median expression value with interquartile range. Normal, matched-normal mucosa (**Po0.01 and ***Po0.0001, Kruskal-Wallis test). (c) miR-296 levels in patients with HCC or matched non-neoplastic liver (***Po0.001, Wilcoxon signed-rank test). (d) Kaplan-Meier curves of relapse-free survival in HCC patients with high or low expression of miR-296. HR, hazard ratio (P ¼ 0.045, log-rank test). Figures 4e and f) . In these experiments, perturbation of miR-296 levels induced defects in cellular orientation, as judged by the position of the golgi apparatus relative to the nucleus (Figures 3a and b) and affected the formation of polarized actin protrusions at the leading edge of directional cell migration (Figures 3c and d ). Finally, we tested whether miR-296 re-expression in MDA-MB231 cells (Figure 4a ) also inhibits tumor growth. We injected control miRNA and mir-296-transfected cells into the fourth mammary fat pads of immunocompromised mice and monitored tumor growth for 3 weeks (Figure 4b ). Mice injected with miR-296 re-expressing cells resulted in reduced tumor growth, compared with controls ( Figure 4c ).
miR-296 regulation of a cell polarity module Consistent with the role of miRs in transcriptional control, changes in miR-296 levels had profound effects on the gene expression profile of tumor cells, as revealed by unsupervised clustering of candidate genes putatively modulated by miR-296 ( Figure 5a ). Out of 107 predicted candidate genes (Supplementary Table 1 ), potentially associated with miR-296 pathways Table 1 ). One of the target genes in the miR-296 gene signature was identified as the cell polarity-cell plasticity module, Scrib (Dow et al., 2007) , an important regulator of apical-basal polarity and directional cell movement (Osmani et al., 2006) . Accordingly, transfection of miR-296 suppressed Scrib protein expression in normal or transformed epithelial cells (Figure 6a and Supplementary Figure 5a ) and significantly inhibited Scrib 3 0 -UTR activity in luciferase reporter assays ( Figure 6b ). In addition, mutagenesis of putative miR-296 binding site in Scrib identified by sequence analysis (Supplementary Figure 5b ) restored 3 0 -UTR activity to the levels of control transfectants (Figure 6b ), validating Scrib as a target gene directly repressed by miR-296. Other putative or predicted target proteins such as BMP8A (Supplementary Table 1 ) or HMGA1 (Wei et al., 2010) were not significantly modulated by miR-296 in our system (Supplementary Figure 5c) . 
Deregulated Scrib expression in human tumors
Mirroring the loss of miR-296 expression in human cancer, Scrib levels were conversely upregulated in primary lesions and distant metastases of colon, lung, breast and stomach cancer (n ¼ 18), as well as HCC (n ¼ 62) (Augello et al., 2009 ), compared with matchednormal parenchyma ( Figure 7a and Supplementary  Figure 6a ). k-Ras mutations on codon 12, Ras V12 or 13, Ras V13 , identified in six patients with colon cancer (40%), did not correlate with expression of miR-296 (P ¼ 0.8, Fisher's exact test; Table 1 ) or its target, Scrib. Scrib protein levels were also increased in hyperplastic, angiogenic and invasive b-islets from RIP-TAg mice, compared with control (4-week-old RIP-Tag) or NT littermates (Supplementary Figure 6b) . In immunohistochemical studies on tumor specimens, the subcellular localization of Scrib was also deregulated, changing from a predominantly membranous localization at cellcell junctions and characteristic of the normal mucosa to a diffuse cytoplasmic staining in primary and metastatic tumor cells (Figure 7a and Supplementary Figure 6a) . In terms of disease outcome, high levels of Scrib mRNA or protein expression in our series of HCC patients, compared with normal liver (Figures 7b and c) significantly correlated with shortened overall survival (Figures 7d and e) , thus mirroring the results with miR-296 expression in the same patient cohort (Figure 1d ).
Discussion
In this study, we have shown that miR-296, a miR initially associated with angiogenic responses (Wurdinger et al., 2008) , is frequently lost during tumor progression in a mouse model of disease and in primary human specimens, correlating with worse outcome. Functionally, loss of miR-296 deregulates a global cell polarity-cell plasticity module, resulting in aberrant overexpression and mislocalization of Scrib in the transformed cell population (Etienne-Manneville, 2008 ) and enhanced tumor cell migration and invasion. Conversely, forced re-expression of miR-296 in highly invasive model breast cancer cell types suppressed tumor growth in vivo.
Although previously implicated in VEGFR2-or PDGFRb-signaling (Wurdinger et al., 2008) , anti-viral mechanisms (Pedersen et al., 2007) , retinoic acidmediated differentiation (Houbaviy et al., 2003; Tay et al., 2008) or to prostate cancer growth and invasion (Wei et al., 2010) , a role of miR-296 in cancer has remained controversial, with studies alternatively reporting increased expression (Hong et al., 2010) or, conversely, downregulation (Yang et al., 2009; Wei et al., 2010) in primary patient series. Here, miR-296 was almost universally downregulated in cancer, compared with matched-normal tissues, and often lost in metastatic lesions. This had profound effects on the transcriptional profile of transformed cells, unrestraining a distinctive 'miR-296-loss' gene signature, enriched in multiple key regulators of cell motility, invasion and metastasis. A recent report (Wei et al., 2010) showed that the oncofetal factor HMGA1 is a direct target of miR-296 in prostate cancer. In our system, HMGA1 was significantly downmodulated at mRNA levels in miR-296 re-expressing cells (Figure 4b ), though its protein levels were not affected by the miR-296 modulation (Supplementary Figure 5c) . Conversely, one of these molecules overexpressed in the miR-296 signature was identified as the cell polarity-cell plasticity module, Scrib (Etienne-Manneville, 2008), which controls apical-basal cell polarity (Bilder et al., 2000) , cell orientation (Osmani et al., 2006) and directional cell miR-296 regulation of tumor progression V Vaira et al movements (Petrie et al., 2009 ) via the assembly of multi-protein complexes at the leading edge of migrating cells (Assemat et al., 2008) .
Although these properties, coupled with the protumorigenic phenotype associated with Scrib loss-offunction (Nagasaka et al., 2010; Wu et al., 2010) , suggested a role in tumor suppression Ouyang et al., 2010; Wu et al., 2010) , our findings point to a far more complex scenario for this pathway in human cancer (Gardiol et al., 2006) . Here, Scrib was found abundantly overexpressed in disparate primary and metastatic epithelial malignancies, correlating with worse patient outcome and mechanistically linked to aberrantly increased tumor cell motility and invasion. Other data also support a causal role of Scrib in human tumorigenesis, as overexpression of Scrib has been observed in colorectal cancer patients correlating with accumulation of cytoplasmic b-catenin (Kamei et al., 2007) , the Scrib locus on 8q24.3 is often amplified in breast and ovarian cancer (Naylor et al., 2005; Kim et al., 2007) , and Scrib was identified as a mediator of HCC progression in vivo (Woo et al., 2009) .
In this context, it is possible that Scrib may alternatively function in tumor suppression or, conversely, tumor progression, depending on the specific cellular context and, in particular, the complement of genetic alterations acquired during disease progression. For instance, Scrib may function to maintain apicalbasal polarity, thus opposing tumorigenicity Wu et al., 2010) at early phases of cellular transformation, whereas more advanced disease stages, characterized by loss of multiple checkpoint/tumor suppressor mechanisms, may exploit aberrantly overexpressed Scrib (Osmani et al., 2006) to enhance random, as opposed to directional cell migration (Petrie et al., 2009) , and thus gaining a critical advantage towards metastatic potential (Hanahan and Weinberg, 2000) . It is also possible that the subcellular mislocalization of Scrib in the cytosol of tumor cells, as characterized here at variance with its distribution at cell-cell junction, may contribute to this diversity of functions and promote aberrant cell migration and invasion. This is consistent with previous observations, in which overexpression of Scrib in astrocytes perturbed apical-basal polarity and promoted the formation of random actin protrusion during cell migration (Osmani et al., 2006) . In summary, we identified miR-296 as a global regulator of cell migration, invasion and tumorigenicity via direct transcriptional repression of a Scrib cell polarity-cell plasticity module (Etienne-Manneville, 2008). These results uncover a more complex scenario than previously thought for how cell polarity-cell plasticity modules may be exploited during human tumorigenesis , whereas the identification of a miR-296-Scrib signaling axis in tumor cell motility (Petrie et al., 2009 ) may open new venues for the development of anti-metastatic therapies in humans.
Materials and methods
Sample collection and RNA purification
All experiments involving animals were approved by an Institutional Animal Care and Use Committee. Pancreatic b-cells were obtained by laser-assisted microdissection (Leica Microsystems, Milan, Italy) from total pancreas of four groups of RIP-TAg transgenic mice (two animals per time point) at the following stages of b-cell tumorigenesis: normal/transgenic b-cells (4 weeks of age), hyperplastic islets (6 weeks of age), angiogenic switch/carcinoma in situ islets (8 weeks of age) and invasive b-cell carcinoma (10 weeks of age). Total pancreas was surgically isolated, formalin-fixed (10% buffered formalin) and paraffin embedded. As controls, NT mice were killed at the same age and processed as above.
Epithelial cells from matched-normal colonic mucosa, dysplastic adenoma, adenocarcinoma or corresponding 
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V Vaira et al metastasis were isolated by laser-assisted microdissection (Leica Microsystems) from formalin-fixed and paraffin embedded blocks of 16 patients with diagnosis of colorectal carcinoma. Epithelial cells from non-neoplastic, tumor or metastatic tissue samples were similarly isolated by laserassisted microdissection (Leica Microsystems) from patients with diagnosis of adenocarcinoma of the breast (n ¼ 4), lung (n ¼ 4), stomach (n ¼ 9), bile ducts (n ¼ 2) or parathyroid tumors (n ¼ 1). Patients' characteristics are summarized in Table 1 . Total RNA was isolated using MasterPure RNA Purification Kit (Epicentre Biotechnologies, Madison, WI, USA), following the manufacturer's instructions and quantified spectrophotometrically.
Total RNA and tissue microarray blocks were available from a series of 62 cases of HCC. Patients' associated clinical follow-up data was described previously (Augello et al., 2009) . Informed consent was obtained from all patients and the study was approved by an Institutional Review Board of the University of Milan, School of Medicine.
miRNA detection
Reverse transcription-PCR-based detection of 132 mature miRs and three mouse-specific reference small nucleolar RNAs (SNO 55, 412 and 142) was carried out from b-cell samples isolated from RIP-TAg transgenic mice or non-transgenic mice, using the miR Reverse Transcription Kit and gene- miR-296 regulation of tumor progression V Vaira et al specific primers and probes (TaqMan MicroRNA Assays, Applied Biosystems, Life Technologies, Carlsbad, CA, USA), according to the manufacturer's specifications. All miRNAs were analyzed in duplicate and instrument raw data (Ct values) were converted into miRNAs relative quantities using the geometrical average of the three small nucleolar RNAs as normalization factor. For each miRNA, fold change ratios were calculated between 6, 8 and 10-week-old RIP-TAg transgenic mice and 4-week-old RIP-TAg animals. A fold change ¼ 10 or 0.1 for over-or under-expression, respectively, was assigned as threshold for significant different expression. Significantly different miRs were analyzed in aged-matched NT mice, as described above. The RNU48 was used as a reference small nucleolar RNA for human tissues or cell lines. For these experiments, miRNA expression relative to reference was calculated using the 2^( ÀDCt) formula. All reagents, primers, kits and instruments were obtained from Applied Biosystems (Life Technologies).
k-Ras mutation analysis
Genomic DNA from tumor samples collected from 16 patients with diagnosis of metastatic colon adenocarcinoma was amplified with the following specific primers for k-Ras gene:
0 . Both strands of k-Ras amplicons were sequenced using BigDye terminators (Applied Biosystems, Life Technologies) and mutations occurring at codons 12 and 13 were identified.
Cells and cell culture conditions
Human colon carcinoma SW1116, HCC HepG2 and HUH-7 and breast adenocarcinoma MDA-MB231, MCF-7, SKBR3 and MDA-MB435 cells were purchased from the American Type Culture Collection. Human embryonic kidney HEK293 cells were a generous gift from Dr Locati (University of Milan, Milan, Italy). Normal HMEC were obtained from GibcoInvitrogen (Life Technologies). Various cell types were seeded at 2 Â 10 6 cells/well in 6-well plates and transfected with 100 pmol of pre-miR-296, antagomir-miR-296, pre-miR-1, pre-miR or Cy3-labeled anti-miR negative controls (Ambion, Life Technologies) in the presence of 5 ml Lipofectamine 2000 in 1 ml of OptiMem medium (Gibco-Invitrogen, Life Technologies). Stable miR-296 or control vector (GeneCopoeia, Rockville, MD, USA) expressing MDA-MB231 cells were generated after Lipofectamine 2000 (Gibco-Invitrogen, Life Technologies) transfection and puromycin (Sigma Aldrich, Milan, Italy) selection for 1 week. Then cells were trypsinized and plated without selection medium. MDA-MB231 with stable expression of miR-296 were validated by quantitative PCR for recombinant miR expression and used for xenograft studies within passage four of culture.
Xenograft breast cancer model
Twelve female CD1 athymic mice were injected subcutaneously in the fourth mammary fat pad with 2 Â 10 5 MDA-MB231 cells, stably transfected with control miR or miR-296 in a total volume of 100 ml of sterile phosphate-buffered saline (six mice per condition). Tumor growth was monitored externally using Scrib siRNAs MDA-MB231 cells were transfected with 100 pmol of siGENOME or control Smart Pool siRNAs (cat. M-010500, D-001206, all from Dharmacon, Lafayette, CO, USA) and 5 ml of Lipofectamine 2000 (Gibco-Invitrogen, Life Technologies), as before. Subsequent to transfection, cells were maintained in complete medium for 24 or 48 h and processed for individual experiments.
Cell cycle, apoptosis and cell viability assays Cell cycle transitions and quantification of hypodiploid DNA content (that is, sub-G1 cell fraction) were determined after 48 or 72 h in transfected cultures by propidium iodide staining and flow cytometry, as described (Romagnoli et al., 2009) . Cells transfected with non-targeting constructs were used as unit sample.
Colony formation assay MDA-MB231 or MCF-7 cells (5 Â 10 3 ) were transfected with the various miRNA constructs and seeded as a single-cell suspension in the presence of 1 ml of 0.7% top agar solution and 1% base agar solid layer after 48 h. Agar for both layers was dissolved in appropriate media supplemented with 10% fetal bovine serum. Cells were cultured at 37 1C, fed twice per week with complete culture medium and plates were stained after 21 days with 0.5 ml of 0.05% crystal violet (Sigma-Aldrich) for 1 h. Colonies with a diameter of at least 100 mm were counted by light microscopy and photographed. 
Isolation of human breast cancer-associated fibroblasts
We isolated tumor-associated fibroblasts from three patients, surgically resected for breast cancer. Briefly, the tissues were minced with blades and digested as previously described (Bauer et al., 2010) . After isolation, cancer-associated fibroblasts were plated in cell culture dishes, cultured in 10% fetal bovine serum supplemented Dulbecco's modified Eagle's medium (Gibco-Invitrogen, Life Technologies) and used for invasion assay of MDA-MB231 cells at the second and third splitting passage.
Motility and directional cell migration assays Subconfluent (70%) cultures of MCF-7, MDA-MB231 or HMEC cells were transfected with the various constructs for 24-48 h. Wounds in the cell monolayer were created using a P200 micropipette tip, after which cells were washed in phosphate-buffered saline and incubated in complete medium for 24 h. For migration assay, three random images ( Â 50) were taken at the time of the scratch and after 24 h. The migration distance (units) was determined as reduction in the wound's gap using NIH Image-J software (National Institute of Health, Bethesda, MD, USA). For directional cell migration, subconfluent monolayers of MDA-MB231 cells were transfected with the various constructs, scratched as above after 66 or 42 h, respectively, and analyzed for golgi orientation after 6 h, by immunofluorescence. The position of the golgi, relative to the nucleus and to the migration front, was scored using Image-J software in cells at the leading edge, as described (Osmani et al., 2006; Dow et al., 2007; Phua et al., 2009) . Golgi staining was performed using Alexa Fluor555-conjugated antibody to GM130 (BD Biosciences, Milan, Italy). The direction of stress fibers was assessed in the same experiments. F-actin was imaged by phalloidin-TRITC staining (Sigma-Aldrich) using an AxioImager Z1 microscope (Carl Zeiss, Go¨ttingen, Germany) were mounted in DAPI I (Abbott, Abbott Park, IL, USA).
Invasion assay MDA-MB231 or HMEC cells (5 Â 10 4 ) transfected with the various constructs were seeded in serum-free medium in matrigel-coated chambers (8.0 mm pores, BD Biosciences). Cells were allowed to migrate across coated inserts using serum-containing medium or cancer-associated fibroblasts as chemoattractant for 24 h. The cells on the apical surface of the insert were scraped off and membranes with invaded cells were fixed in 100% methanol, stained with toluidine blue (SigmaAldrich) and mounted on microscope slides. Invading cells were counted after photographing the membranes and both the peripheral and the central areas were evaluated.
Anoikis assay MCF-7 or MDA-MB231 cells were seeded (2 Â 10 5 ) in poly-HEMA (20 mg/ml, Sigma-Aldrich)-coated 6-well plates after transfection with the various miRNA-mimics for 48 h or with the indicated siRNA for 24 h. Cells were harvested after additional 24 h and viability was assessed by propidium iodide content and flow cytometry (fluorescence-activated cell sorting). When PKH26 staining was performed (Sigma-Aldrich), 2 Â 10 7 A549 or MDA-MB231 cells were labeled the day before transfection, following manufacturer protocol.
miR-296 modulated genes analysis
The mRNA level of candidate genes (n ¼ 107; Supplementary Table 1) was investigated in MDA-MB231 cells transfected with miR-296 or control constructs using TaqMan Gene Expression assays (Applied Biosystems, Life Technologies). TATA-binding protein was used as housekeeping gene for target genes relative quantification, using the 2^( ÀDCt) formula. Relative quantifications were median-normalized and log2 transformed to generate an unsupervised hierarchical clustering. A 1.5-fold cutoff was used to select genes modulated by transfection of anti-miR-296 or p-miR-296 relative to control, which were further analyzed using Ingenuity Pathway software (Ingenuity Systems Inc., Redwood City, CA, USA). Functional profiling using Gene Ontology terms for biological process, molecular function and cellular component were conducted for miR-296 predicted targets identified by at least four algorithms (n ¼ 145), using GOTM tool (http://bioinfo. vanderbilt.edu/gotm). As reference gene set, we used the human genome and the top 10 functional categories (most significant P-values obtained using the hypergeometric test adjusted for multiple comparisons) with a minimum number of four required genes were identified (Supplementary Table 2 ).
Luciferase miRNA target reporter assay Mutation in miR-296 seeding sequence within Scrib 3 0 -UTR were created using QuikChangeII XL site directed mutagenesis kit (Stratagene, Agilent Technologies, Santa Clara, CA, USA). Vectors containing full-length wild type or mutated 3 0 -UTR sequences of Scrib gene or control sequence and dual luciferase reporter genes were purchased from GeneCopoeia. HEK293 cells were co-transfected, as described above, with 1 mg plasmid containing target gene 3 0 -UTR or control sequence in the presence of 50 nM pre-miR-296, anti-miR-296, control oligonucleotides or unrelated miRNA constructs (anti-let-7 g and premiR-1). Cells were lysed after 30 h and firefly to renilla luciferase ratios was measured with a dual luciferase assay (Promega, Milan, Italy) using a Synergy 2 luminometer (BioTek, Winooski, VT, USA). Normalized luciferase ratios were determined for all combinations tested of miRNAs and vectors.
Immunoblotting, immunohistochemistry and immunofluorescence For immunoblotting, aliquots of MDA-MB231, MCF-7 or HMEC cells were harvested 48 or 72 h post-transfection and solubilized in 150 ml of RIPA buffer supplemented with 1 Â complete protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Cell lysates (50 mg) were separated by electrophoresis on 6 or 12% SDS-polyacrylamide gels, transferred to PVDF membranes (Millipore, Billerica, MA, USA), probed with 1 mg/ml of antibodies against Scrib (Santa Cruz Biotechnology, Santa Cruz, CA, USA), b-actin (Sigma-Aldrich), BMP8A (Novus Biologicals, Littleton, CO, USA), HMGA1 (LSBio, Seattle, WA, USA) or cytokeratin AEI-AE3 (Dako, Milan, Italy) and reactive bands were visualized with ECL Plus reagents (GE Healthcare, Milan, Italy). Cancer-associated fibroblasts were visualized by immunofluorescence staining with an antibody to vimentin (Dako). Immunohistochemical staining of formalin-fixed and paraffin embedded tissue samples collected from patients with metastatic carcinomas or HCC was carried out using an antibody to Scrib (10 mg/ml; Santa Cruz Biotechnologies) for 1 h at 22 1C, followed by counterstaining with hematoxylin. As negative control, slides were incubated with dilution buffer instead of primary antibody. Slides were scored by light microscopy and photographed images were arranged with Photoshop for Windows. Cytoplasmatic and membranous Scrib immunoreactivity was scored as negative (0), weak (1), moderate (2) or strong (3) by two authors (GC and SB) independently.
Statistical analysis and clinical validation of miR-296 and Scrib
All experiments were performed in duplicate and performed at least three times. Differences among samples were analyzed using Student's t-test, unless otherwise specified. The correlamiR-296 regulation of tumor progression V Vaira et al tion between k-Ras mutation status and miR-296 in colorectal carcinoma patients was determined using the Fisher's exact test. For survival analysis, the Kaplan-Meier method was used. To explore a potential association between miR expression and metastatic relapse, patients were assigned to two groups, depending on miR-296 relative expression in tumor versus the averaged non-neoplastic counterparts. A miR-296 ratio of p0.5 was used for the 'low' group, whereas a miR-296 value of 40.5 was used for the 'high' group. To estimate the association of Scrib mRNA or protein expression to tumor recurrence, HCCs patients were categorized in two groups according to Scrib expression value as for the miR. The two-sided log-rank test was used to compare survival curves. Statistical analyses were performed using GraphPad Prism version 4 (GraphPad Inc., La Jolla, CA, USA) or Ministat 2.1 software (www.bayes.it, Milan, Italy). A Po0.05 was considered as statistically significant.
